Skip to main content
. 2013 Apr 15;14:127. doi: 10.1186/1471-2105-14-127

Figure 2.

Figure 2

Dependence on the type of antigen. The relative number of cancer cells after one year of treatment compared to the tumour size at the beginning of the simulation is depicted. The mean number of cancer cells at the end of simulation is shown. Data were obtained from 500 simulations. A: MHC-genotype is HLA-A*01 | HLA-B*08 | HLA-DPA1/DPB1 | HLA-DRB3. B: MHC genotype is HLA-A*02 | HLA-B*44 | HLA-DQA1/DQB1 | HLA-DRB5. For all experiments, one hundred initial cancer cells were simulated within 5 μl of blood that were treated with injections of peptides emulgated in adjuvant starting at time point zero and being repeated five times at an interval of 28 days. Antigens were chosen from over-expression data in kidney tumours. Two MHC I-binding peptides and two MHC II-binding peptides were injected. Description of antigen UniProt-IDs: A0FJ57_HUMAN: Wilms tumour 1; A0PHL1_HUMAN: RAS-like family 11 member B variant A; 4EBP1_HUMAN: Eukaryotic translation initiation factor 4E-binding protein 1; A0RZB6_HUMAN: Endoplasmic reticulum chaperone; A4UJ43_HUMAN: Brain type mu-glutathione S-transferase.